Department of Pharmacology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Neurochem Res. 2024 Feb;49(2):363-378. doi: 10.1007/s11064-023-04041-4. Epub 2023 Oct 9.
Cannabidiol (CBD) is a promising neurological agent with potential beneficial effects on memory and cognitive function. The combination of CBD and topiramate in the treatment of some neurological diseases has been of great interest. Since Topiramate-induced memory loss is a major drawback of its clinical application and the overall effect of the combination of CBD and topiramate on memory is still unclear, here we investigated the effect of CBD on topiramate-induced memory loss and the underlying molecular mechanisms. A one trial step-through inhibitory test was used to evaluate memory consolidation in rats. Moreover, the role of N-methyl-D-aspartate receptors (NMDARs) in the combination of CBD and topiramate in memory consolidation was evaluated through the intra-CA1 administration of MK-801 and NMDA. Western blot analysis was used to evaluate variations in brain-derived neurotrophic factor (BDNF) and phosphorylated cyclic AMP response element-binding protein (pCREB)/CREB ratio in the prefrontal cortex (PFC) and hippocampus (HPC). While the intraperitoneal (i.p.) administration of topiramate (50, 75, and 100 mg/kg) significantly reduced inhibitory time latency, the i.p. administration of CBD (20 and 40 mg/kg) could effectively reverse these effects. Similarly, the sub-effective doses of NMDA plus CBD (10 mg/kg) could improve the topiramate-induced memory loss along with an enhancement in BDNF and pCREB expression in the PFC and HPC. Contrarily, the administration of sub-effective doses of the NMDAR antagonist (MK-801) diminished the protective effects of CBD (20 mg/kg) on topiramate-induced memory loss associated with decreased BDNF and pCREB levels in the PFC and HPC. These findings suggest that CBD can improve topiramate-induced memory impairment, partially by the NMDARs of the PFC and HPC, possibly regulated by the CREB/BDNF signaling pathway.
大麻二酚(CBD)是一种有前途的神经递质,对记忆和认知功能有潜在的有益影响。CBD 与托吡酯联合治疗一些神经疾病引起了极大的兴趣。由于托吡酯引起的记忆丧失是其临床应用的主要缺点,并且 CBD 与托吡酯联合使用对记忆的总体效果尚不清楚,因此我们研究了 CBD 对托吡酯引起的记忆丧失的影响及其潜在的分子机制。在大鼠中使用单次试验步降抑制试验来评估记忆巩固。此外,通过 CA1 内注射 MK-801 和 NMDA 来评估 CBD 与托吡酯联合治疗在记忆巩固中的 N-甲基-D-天冬氨酸受体(NMDARs)的作用。通过 Western blot 分析评估前额叶皮层(PFC)和海马(HPC)中脑源性神经营养因子(BDNF)和磷酸化环 AMP 反应元件结合蛋白(pCREB)/CREB 比值的变化。虽然腹腔内(i.p.)给予托吡酯(50、75 和 100mg/kg)可显著降低抑制时间潜伏期,但腹腔内给予 CBD(20 和 40mg/kg)可有效逆转这些作用。同样,NMDA 加 CBD 的亚有效剂量(10mg/kg)可改善托吡酯引起的记忆丧失,并增强 PFC 和 HPC 中的 BDNF 和 pCREB 表达。相反,给予亚有效剂量的 NMDAR 拮抗剂(MK-801)可减弱 CBD(20mg/kg)对托吡酯引起的记忆丧失的保护作用,同时降低 PFC 和 HPC 中 BDNF 和 pCREB 水平。这些发现表明,CBD 可以改善托吡酯引起的记忆障碍,部分通过 PFC 和 HPC 的 NMDAR,可能通过 CREB/BDNF 信号通路调节。